The nation of Zimbabwe has turned down a substantial American health deal worth $367m (272 million pounds) over five years due to Washington's request for sensitive biological samples.
This rejection became public following a internal memorandum from December was disclosed, which showed Head of State Emmerson Mnangagwa believed the agreement was "unbalanced".
A government spokesman has since stated that the United States was seeking health data for research and commercial purposes while was unwilling to share the resulting advantages from future vaccines.
"We must now begin the difficult and regrettable task of winding down our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had donated more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has urged continued talks to reach a deal acceptable to all parties so the country's critical HIV treatment initiative can be sustained.
Wider Background
This development follows a similar case in Kenya, where a high court suspended a similar deal with the US after legal challenges were filed about the security of citizens' health data.
Since returning to the presidency last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had administered aid for the US government, but Trump claimed its spending was "inefficient" and his administration was pursuing direct bilateral agreements to boost transparency and accountability.
According to statements, Sixteen African countries have to date signed these new health pacts, representing over $18.3bn of fresh investment.
Details of the Rejected Deal
This assistance for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this partnership might have yielded immense advantages for the people of Zimbabwe, especially the 1.2 million presently on HIV treatment through American-funded programmes," the Ambassador said.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"The proposal required Zimbabwe to share its biological resources and data for a long time, without any corresponding guarantee of benefiting from any medical innovations – like new medicines or tests – that might result from that provided information," Mangwana explained.
"In essence, our country would provide the raw materials for scientific discovery without any assurance that the end products would be accessible to our citizens should a future health crisis arise."
National Interest and International Frameworks
He also said that the US's withdrawal from the global health body and its push of bilateral health agreements were undermining frameworks previously set up via the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to manage potential pandemics.
"This system is designed to ensure that when a country provides its information, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage continued dialogue with our US partners on how subsequent co-operation could be structured in a manner that respects the independence and dignity of each country."
Health Experts Reaction
A leading public health body expressed it recognised the government's concerns, but recommended that talks must proceed given that much of the country's Aids initiatives depended on external financing.
"If specific concerns arise, such as those relating to data governance or implementation frameworks, these can frequently be resolved through technical clarification and mutually agreed protections," it added.
The situation emphasises the ongoing tensions between accepting vital foreign assistance and protecting a country's data in an increasingly data-driven world.